COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS
The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
1 . An amino lipid having the following structure (I):
wherein
R 1 and R 2 are either the same or different and independently optionally substituted C 12 -C 24 alkyl, optionally substituted C 12 -C 24 alkenyl, optionally substituted C 12 -C 24 alkynyl, or optionally substituted C 12 -C 24 acyl;
R 3 and R 4 are either the same or different and independently optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 alkenyl, or optionally substituted C 1 -C 6 alkynyl or R 3 and R 4 may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms chosen from nitrogen and oxygen;
R 5 is either absent or present and when present is hydrogen or C 1 -C 6 alkyl;
m, n, and p are either the same or different and independently either 0 or 1 with the proviso that m, n, and p are not simultaneously 0;
q is 0, 1, 2, 3, or 4; and
Y and Z are either the same or different and independently O, S, or NH.
2 . The amino lipid of claim 1 , having the structure:
3 . An amino lipid having a structure selected from the group consisting of:
4 . A lipid particle comprising an amino lipid of claim 1 .
5 . The lipid particle of claim 4 , comprising the amino lipid of claim 2 .
6 . The lipid particle of claim 4 , wherein the particle further comprises a neutral lipid and a lipid capable of reducing particle aggregation.
7 . The lipid particle of claim 6 , wherein the lipid particle consists essentially of:
(i) DLin-K-DMA;
(ii) a neutral lipid selected from DSPC, POPC, DOPE, and SM;
(iii) cholesterol; and
(iv) PEG-S-DMG, PEG-C-DOMG or PEG-DMA,
in a molar ratio of about 20-60% DLin-K-DMA:5-25% neutral lipid:25-55% Chol:0.5-15% PEG-S-DMG, PEG-C-DOMG or PEG-DMA.
8 . A lipid particle, wherein the lipid particle comprises:
(i) one or more cationic or amino lipids;
(ii) one or more neutral lipids selected from DSPC, POPC, DOPE, and SM;
(iii) cholesterol; and
(iv) PEG-C-DOMG,
in a molar ratio of about 20-60% cationic lipid or amino lipid:5-25% neutral lipid:25-55% cholesterol:0.5-15% PEG-C-DOMG.
9 . The lipid particle of claim 8 , wherein the amino lipid is an amino lipid of claim 1 .
10 . The lipid particle of claim 4 , further comprising a therapeutic agent.
11 . The lipid particle of claim 10 , wherein the therapeutic agent is a nucleic acid.
12 . The lipid particle of claim 11 , wherein the nucleic acid is a plasmid.
13 . The lipid particle of claim 11 , wherein the nucleic acid is an immunostimulatory oligonucleotide.
14 . The lipid particle of claim 11 , wherein the nucleic acid is selected from the group consisting of: a siRNA, a microRNA, an antisense oligonucleotide, and a ribozyme.
15 . The lipid particle of claim 14 , wherein the nucleic acid is a siRNA.
16 . A pharmaceutical composition comprising a lipid particle of claim 10 and a pharmaceutically acceptable excipient, carrier, or diluent.
17 . A method of modulating the expression of a polypeptide by a cell, comprising providing to a cell the lipid particle of claim 10 .
18 . The method of claim 17 , wherein the therapeutic agent is selected from a siRNA, a microRNA, an antisense oligonucleotide, a plasmid capable of expressing a siRNA, a microRNA, and an antisense oligonucleotide, and wherein the siRNA, microRNA, or antisense RNA comprises a polynucleotide that specifically binds to a polynucleotide that encodes the polypeptide, or a complement thereof, such that the expression of the polypeptide is reduced.
19 . The method of claim 17 , wherein the nucleic acid is a plasmid that encodes the polypeptide or a functional variant or fragment thereof, such that expression of the polypeptide or the functional variant or fragment thereof is increased.
20 . A method of treating a disease or disorder characterized by overexpression of a polypeptide in a subject, comprising providing to the subject the pharmaceutical composition of claim 16 , wherein the therapeutic agent is selected from a siRNA, a microRNA, an antisense oligonucleotide, a plasmid capable of expressing a siRNA, a microRNA, and an antisense oligonucleotide, and wherein the siRNA, microRNA, or antisense RNA comprises a polynucleotide that specifically binds to a polynucleotide that encodes the polypeptide, or a complement thereof.
21 . A method of treating a disease or disorder characterized by underexpression of a polypeptide in a subject, comprising providing to the subject the pharmaceutical composition of claim 16 , wherein the therapeutic agent is a plasmid that encodes the polypeptide or a functional variant or fragment thereof.
22 . A method of inducing an immune response in a subject, comprising providing to the subject the pharmaceutical composition of claim 16 , wherein the therapeutic agent is an immunostimulatory oligonucleotide.
23 . The method of claim 22 , wherein the pharmaceutical composition is provided to the patient in combination with a vaccine or antigen.
24 . A vaccine comprising the lipid particle of claim 13 and an antigen associated with a disease or pathogen.
25 . The vaccine of claim 24 , wherein said antigen is a tumor antigen.
26 . The vaccine of claim 24 , wherein said antigen is a viral antigen, a bacterial antigen, or a parasitic antigen.